Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Washington Post


Proactive Investors USA & Canada

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma
Washington Post
Drugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair. The maker of diabetes pill Januvia beat Wall Street's
Merck tops view, newer drugs cushion asthma drug blowGlobe and Mail
Merck Q3 earnings edge up despite decline in salesProactive Investors USA & Canada
Merck's Profit Rises 2.2%Wall Street Journal
Chicago Tribune –Fox Business
all 221 news articles »

View full post on asthma – Google News

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Newser


Globe and Mail

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma
Newser
The maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. Merck, based in Whitehouse Station, N.J
Merck tops view, newer drugs cushion asthma drug blowGlobe and Mail
Merck posts mixed results for third quarterChicago Tribune
MERCK & CO., INC. : Merck 3rd-Quarter Profit Up 2.2%; Narrows Year View4-traders
Fox Business –The Markets Are Open (blog)
all 161 news articles »

View full post on asthma – Google News

Vectura rises after swinging to first-half profit – The Guardian (blog)

Vectura rises after swinging to first-half profit
The Guardian (blog)
Vectura, which specialises in drugs for respiratory diseases such as asthma and chronic obstructive pulmonary (COPD) disease, enjoyed a 5% bounce in its share price after swinging to a first-half profit. The shares climbed 3.25p to 68.7p.
VECTURA GROUP PLC : Half Yearly Report4-traders (press release)

all 4 news articles »

View full post on asthma – Google News

OP-ED: Lung health vs. pollute for profit – Yorkdispatch.com


Los Angeles Times

OP-ED: Lung health vs. pollute for profit
Yorkdispatch.com
This pollutant is also a known trigger of asthma attacks and can even worsen the severity of these attacks, thereby increasing the need for people with not only asthma but also emphysema, chronic bronchitis and other serious lung diseases to require
Air pollution making children sickAustin American-Statesman
A closer look: Setting a 'safer' ozone levelLos Angeles Times
Report: higher smog risk for US LatinosMiamiHerald.com
Hawaii Reporter –Toledo Blade
all 20 news articles »

View full post on asthma – Google News

Cornerstone Therapeutics profit falls on expenses – BusinessWeek

Cornerstone Therapeutics profit falls on expenses
BusinessWeek
Sales of the asthma treatment Zyflo CR and Zyflo doubled to $8.8 million. For the full year, the company earned $6.2 million or 24 cents per share, down from $10.2 million, or 54 cents per share, in 2009. Revenue rose to $125.3 million from $109.6
Critical Therapeutics Inc. Reports Operating Results (10-K)GuruFocus.com

all 6 news articles »

View full post on asthma – Google News